
Annual E.S. Garnett Memorial Lecture

Viability testing in the post STICH Era Was STICH Viable and the role of PET in Viability



presented by Sharmila Dorbala MD, MPH

Monday, May 7, 2018 4:30 - 6:00 p.m. PHRI Auditorium 237 Barton Street East Hamilton ON L8L 2X2

Reception to follow 6:00 - 7:00 p.m.

This event is an accredited group learning activity as defined by the maintenance of certification programme of the Royal College of Physicians and Surgeons of Canada.

Objectives

- 1. Define the utility of viability imaging in the management of ischemic heart disease
- 2. Discuss the design and salient results of the STICH trial
- 3. Current clinical role of ¹⁸F-FDG PET viability imaging in ischemic left ventricular dysfunction.



Sharmila Dorbala, MD, MPH is the Director of Nuclear Cardiology, Brigham and Women's Hospital, and Associate Professor of Radiology, Harvard Medical School. After receiving her medical degree in India, Dr. Dorbala came to St. Luke's Roosevelt Hospital Center, New York City in 1994 where she completed her Residency in Internal Medicine, and Fellowship in Cardiovascular Diseases, Nuclear Cardiology, and Advanced Cardiovascular Imaging. In 2001, after completion of her imaging fellowship, she was recruited to a faculty position at the Brigham and Women's Hospital.

Dr. Dorbala is also the Vice President of the American Society of Nuclear Cardiology, past president of the Cardiovascular Council of the Society of Nuclear Medicine and Molecular Imaging. She also serves as an Associate Editor of the Journal of Nuclear Cardiology and for the past 10 years had served as an Associate Editor of Circulation Cardiovascular Imaging.

Dr. Dorbala has practiced cardiac PET for over 10 years and taught cardiac PET at the American Society of Nuclear Cardiology Educational Courses. In her research, she uses cardiac PET information to stratify risk in persons with ischemic heart diseases. More recently, Dr. Dorbala's group has pioneered the use of 18F-florbetapir PET to precisely characterize amyloid heart disease in humans. With funding from the National Institutes of Health, American Heart Association, and Foundations, Dr. Dorbala's group is currently focused on molecular imaging cardiac amyloidosis, a highly fatal form of heart failure.







CARDIOLOGY GRAND ROUNDS > Tuesday, May 8, 2018 | 8:00 – 9:00 a.m.

Cardiac PET Perfusion - Why should I order a PET?

Objectives 1. List the advantages of PET compared to SPECT myocardial perfusion imaging

- 2. Discuss clinical indications for cardiac perfusion PET
- 3. Outline the added value of quantitative PET perfusion and coronary flow reserve

Location | PHRI Auditorium, 237 Barton Street East, Hamilton ON L8L 2X2